Compare KORE & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | CALC |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.5M | 91.5M |
| IPO Year | N/A | N/A |
| Metric | KORE | CALC |
|---|---|---|
| Price | $4.36 | $6.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $14.50 |
| AVG Volume (30 Days) | 51.0K | ★ 149.0K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,408,000.00 | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.06 | N/A |
| 52 Week Low | $1.30 | $1.42 |
| 52 Week High | $4.88 | $6.40 |
| Indicator | KORE | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 73.00 |
| Support Level | $4.10 | $4.64 |
| Resistance Level | $4.50 | $6.40 |
| Average True Range (ATR) | 0.26 | 0.50 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 58.33 | 84.85 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.